Alnylam Pharmaceuticals
ALNY
#649
Rank
S$49.74 B
Marketcap
S$372.56
Share price
0.68%
Change (1 day)
7.39%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): S$1.11 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are S$4.28 Billion. In 2025 the company made an earning of S$0.80 Billion, an increase over its 2024 earnings that were of -S$0.3 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) S$1.11 B38.8%
2025 S$0.80 B-369.48%
2024 -S$0.3 Billion-24.59%
2023 -S$0.4 Billion-67.84%
2022 -S$1.24 Billion36.93%
2021 -S$0.91 Billion-8.04%
2020 -S$0.98 Billion-15.66%
2019 -S$1.17 Billion12.23%
2018 -S$1.04 Billion62.91%
2017 -S$0.64 Billion17.78%
2016 -S$0.54 Billion43.44%
2015 -S$0.38 Billion60.69%
2014 -S$0.24 Billion98.2%
2013 -S$0.12 Billion
2011 -S$69.6 Million27.48%
2010 -S$54.6 Million-10.92%
2009 -S$61.29 Million95.77%
2008 -S$31.31 Million
2006 -S$50.16 Million-9.13%
2005 -S$55.2 Million34.74%
2004 -S$40.97 Million36.79%
2003 -S$29.95 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
S$20.03 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$9.72 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$6.54 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-S$0.9 Billion-180.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-S$60.22 Million-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-S$0.21 Billion-118.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$2.88 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S$0.43 B-60.31%๐Ÿ‡บ๐Ÿ‡ธ USA